These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20548940)

  • 21. HIV RNA suppression and immune restoration: can we do better?
    Pinzone MR; Di Rosa M; Cacopardo B; Nunnari G
    Clin Dev Immunol; 2012; 2012():515962. PubMed ID: 22489250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reemergence of plasma viremia after discontinuation of HAART.
    AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019445
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound.
    Tomasoni L; Patroni A; Uccelli MC; Gargiulo F; Torti C; Carosi G; Castelli F
    J Infect Dis; 2002 Aug; 186(3):445-6. PubMed ID: 12134248
    [No Abstract]   [Full Text] [Related]  

  • 26. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali.
    Merci NM; Emerence U; Augustin N; Habtu M; Julie I; Angelique T; Jessica B; Cynthia A; Penda AT
    Pan Afr Med J; 2017; 26():14. PubMed ID: 28450993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
    Dinoso JB; Kim SY; Wiegand AM; Palmer SE; Gange SJ; Cranmer L; O'Shea A; Callender M; Spivak A; Brennan T; Kearney MF; Proschan MA; Mican JM; Rehm CA; Coffin JM; Mellors JW; Siliciano RF; Maldarelli F
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9403-8. PubMed ID: 19470482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
    Nicastri E; Palmisano L; Sarmati L; D'Ettorre G; Parisi S; Andreotti M; Buonomini A; Pirillo FM; Narciso P; Bellagamba R; Vullo V; Montano M; Di Perri G; Andreoni M
    Curr HIV Res; 2008 May; 6(3):261-6. PubMed ID: 18473790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.
    Darcissac EC; Vidal V; De La Tribonniere X; Mouton Y; Bahr GM
    Clin Exp Immunol; 2001 Nov; 126(2):287-94. PubMed ID: 11703373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.
    Baldanti F; Paolucci S; Gulminetti R; Maserati R; Migliorino G; Pan A; Maggiolo F; Comolli G; Chiesa A; Gerna G
    Antiviral Res; 2001 Jun; 50(3):197-206. PubMed ID: 11397507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV vaccination].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():68-9. PubMed ID: 19031568
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia.
    Voltersvik P; Albrektsen G; Ulvestad E; Dyrhol-Riise AM; Sørensen B; Asjö B
    J Acquir Immune Defic Syndr; 2003 Dec; 34(4):358-67. PubMed ID: 14615653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
    Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
    AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.
    Feeney ME; Draenert R; Roosevelt KA; Pelton SI; McIntosh K; Burchett SK; Mao C; Walker BD; Goulder PJ
    J Immunol; 2003 Dec; 171(12):6968-75. PubMed ID: 14662905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
    Weissbrich B; Langmann P; Schubert J; Jassoy C; Klinker H
    Eur J Med Res; 2003 Nov; 8(11):495-8. PubMed ID: 14644704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.
    Hatano H; Vogel S; Yoder C; Metcalf JA; Dewar R; Davey RT; Polis MA
    AIDS; 2000 Jul; 14(10):1357-63. PubMed ID: 10930150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
    Persaud D; Siberry GK; Ahonkhai A; Kajdas J; Monie D; Hutton N; Watson DC; Quinn TC; Ray SC; Siliciano RF
    J Virol; 2004 Jan; 78(2):968-79. PubMed ID: 14694128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.
    Lerner P; Guadalupe M; Donovan R; Hung J; Flamm J; Prindiville T; Sankaran-Walters S; Syvanen M; Wong JK; George MD; Dandekar S
    J Virol; 2011 May; 85(10):4772-82. PubMed ID: 21345945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.